Sanofi has paid the upfront fee and committed to discovery, development and commercial milestones of over $400 million to get ...

Cassava Sciences is laying off 10 employees —a third of its workforce—as the biotech seeks to conserve cash in the wake of ...

After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...

Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to ...

QPS Holdings, a contract research organization with offices in the U.S., Asia and Europe, has named Ryght AI its ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

Things are heating up for FIRE1, which posted a $120 million funding round to support its implant for tracking the hidden ...

After professing a hearty appetite for tuck-in M&A last year and signing a string of smaller deals, Stryker is now opening ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. | The Fierce Biotech Fundraising Tracker records ...

Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies ...

Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populatio | ...

Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 ...